针对向癌症治疗的强烈焦点粘附激酶抑制剂的β-glucuronidase响应性蛋白结合原药
Louna Mossino1, Rémi Châtre2, Mélanie Poinsot1
1Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques (LCBPT), CNRS UMR8601, Université de Paris Cité, 45 rue des Saints-Pères, 75006, Paris, France.
ChemMedChem
|December 29, 2025
概括
一种新型前药通过选择性释放FAK抑制剂来向固体瘤,显示出显著的乳腺癌细胞生长抑制和G2/M阶段停止. 这种方法提供了一个有前途的FAK向癌症治疗.
科学领域:
- 在瘤学瘤学.
- 药物运输 药物运输 药物运输
- 生物化学 生物化学
背景情况:
- 焦点粘附激酶 (FAK) 在癌症的发展和恶性瘤中至关重要.
- 目前的FAK抑制剂缺乏癌细胞选择性和特异性,阻碍了临床转化.
- 针对FAK仍然是癌症治疗的关键策略.
研究的目的:
- 在固体瘤中合成和评估用于选择性FAK抑制剂输送的前药物.
- 调查前药物的激活机制和治疗疗效.
- 评估前药对乳腺癌细胞周期进展的影响.
主要方法:
- 一种对三聚体β-葡萄糖化酶有反应的专蛋白结合原药的合成.
- 使用MDA-MB-231乳腺癌细胞进行体外生物评估.
- 关于细胞循环进展和FAK抑制的机制研究.
主要成果:
- 这种前药物在β-葡萄糖酶激活后显示出强大的乳腺癌细胞生长抑制 (IC50 = 0.63 ± 0.02μM).
- 酶激活导致细胞周期在G2/M阶段停止.
- 结合白蛋白的部分促进了在固体瘤内的向输送.
结论:
- 开发的前药物能够选择性地提供FAK抑制剂,克服当前治疗方法的局限性.
- 这种对β-glucuronidase反应的系统显示了针对FAK向癌症治疗的巨大潜力.
- 前药物策略需要进一步研究固体瘤治疗.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)

